Zacks Investment Research upgraded shares of Cempra (NASDAQ:MLNT) from a sell rating to a hold rating in a research report released on Thursday, November 16th.
According to Zacks, “Cempra Holdings, LLC is a pharmaceutical company engaged in developing antibiotics for the treatment of bacterial infectious diseases. It focuses on developing antibiotics for treating respiratory tract, skin and skin structure infections and to target the growing problem of antimicrobial resistance. Cempra Holdings, LLC is headquartered in Chapel Hill, North Carolina. “
Other equities analysts have also issued reports about the stock. Stifel Nicolaus reiterated a hold rating and issued a $4.00 price objective on shares of Cempra in a research report on Thursday, August 10th. Jefferies Group restated a hold rating and set a $3.00 target price on shares of Cempra in a research report on Thursday, September 14th. ValuEngine upgraded shares of Cempra from a sell rating to a hold rating in a research report on Wednesday, November 8th. Robert W. Baird upgraded shares of Cempra from an underperform rating to a neutral rating and set a $2.00 target price on the stock in a research report on Wednesday, November 1st. Finally, Roth Capital lowered shares of Cempra from a buy rating to a neutral rating and decreased their target price for the stock from $8.00 to $4.00 in a research report on Thursday, August 10th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. Cempra has an average rating of Hold and an average target price of $6.05.
Cempra (NASDAQ MLNT) traded down $0.20 during trading hours on Thursday, reaching $16.00. 255,937 shares of the company were exchanged, compared to its average volume of 227,093. Cempra has a 1 year low of $10.25 and a 1 year high of $41.00. The company has a debt-to-equity ratio of 0.03, a quick ratio of 11.49 and a current ratio of 11.49.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.dispatchtribunal.com/2017/12/04/cempra-inc-mlnt-lifted-to-hold-at-zacks-investment-research.html.
Melinta Therapeutics, Inc, formerly Cempra, Inc, is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).
Get a free copy of the Zacks research report on Cempra (MLNT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cempra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.